Christine Ann Franke

20050042756, Feb 24, 2005

Nov 3, 2003

10/698439

Christine Franke - Albany OR, US
Tove Bolken - Jefferson OR, US
Kevin Jones - Albany OR, US
Dennis Hruby - Albany OR, US

C12N015/74
C12N001/21

435471000, 435252300

The present invention provides two new chromosomal integration sites for expression of foreign genes have been developed in (). One integration site is intergenic between orfA and orfB in an operon of unknown function. The other site is intragenic within the lacG gene, which encodes phospho-β-galactosidase, and is part of the lactose (lac) operon. The emm6 gene from was integrated in a stable configuration into the chromosome of at each of these integration sites, and in both cases the recombinant bacteria expressed the M6 protein on their surface. Furthermore, expression from the lacG site within the lactose operon was shown to be regulated by growth on lactose. Identification of these new chromosomal insertion sites provides the ability to express multiple foreign genes from the same recombinant and the potential for modulating expression in vitro or in vivo by the use of a biosynthetic metabolite.

6306619, Oct 23, 2001

Jun 29, 2000

9/605858

Hal C. Jones - Corvallis OR
Christopher Liu - Cambridge MA
Scott J. Hultgren - Town and Country MO
Dennis E. Hruby - Albany OR
Christine A. Franke - Albany OR
Amy K. Evans - West Linn OR

Washington University - St. Louis MO
Siga Pharmaceuticals - New York NY

C12Q 137

435 23

The DegP (HtrA) protease is a multifunctional protein essential for the removal of misfolded and aggregated proteins in the periplasm. The present invention provides an assay for inhibitors of DegP activity, comprising mixing a suspected inhibitor of DegP activity with DegP and a suitable substrate (preferably a native substrate of DegP such as PapA) and detecting changes in DegP activity. DegP has been shown to be essential for virulence in several Gram negative pathogens. Only three natural targets for DegP have been described: colicin A lysis protein (Cal), pilin subunits (K88, K99, Pap) and recently HMW1 and HMW2 from Hemophilus influenzae. In vitro, DegP has shown weak protease activity on casein and several other non-native substrates. The present inventors have identified the major pilin subunit of the Pap pilus, PapA, as a native DegP substrate and demonstrated binding and proteolysis of this substrate in vitro. Using an NH. sub.

63129558, Nov 6, 2001

Apr 29, 1999

9/301456

Dennis E. Hruby - Albany OR
Christine A. Franke - Albany OR

Siga Pharmaceuticals - New York NY

C12N 1501

435441

The present invention features gram-positive bacteria resistant to 5-fluorodeoxyuridine (FUdR). Such bacteria will preferably be commensal, and will not be resistant to antibiotics. Bacteria according to the present invention may also be transformed with DNA encoding an antigenic protein. Such transformed bacteria may be used to formulate a vaccine, in order to stimulate an immune response to the antigenic protein in a patient. The present invention further provides a method for isolating gram-positive bacteria resistant to FUdR.